论文部分内容阅读
以曲妥珠单抗为基础的化疗是目前治疗HER-2阳性晚期胃癌的标准方法,能有效延长晚期HER-2阳性胃癌患者总生存期和无进展生存率。由于手术标本较少,HER-2阳性胃癌曲妥珠单抗治疗后的组织病理学变化迄今尚未阐明。作者旨在描述HER-2阳性胃癌曲妥珠单抗治疗后胃癌组织反应及其与HER-2状态的相关性。
Trastuzumab-based chemotherapy is the standard method for the treatment of HER-2-positive advanced gastric cancer and can effectively prolong the overall and progression-free survival of patients with advanced HER-2-positive gastric cancer. Due to the small number of surgical specimens, HER-2-positive gastric cancer trastuzumab histopathological changes have not yet been elucidated. The authors aimed to describe the response of gastric cancer tissue following HER-2 positive gastric trastuzumab treatment and its association with HER-2 status.